Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines

Hui Zhao, Vidhi Desai, Jian Wang, David M. Epstein, Mark Miglarese, Elizabeth Buck

Mol Cancer Ther (2012) 11 (2): 503–513.

https://doi.org/10.1158/1535-7163.MCT-11-0327

Published: 08 February 2012

View article titled, Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines

Journal Articles

Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors

Richard Gedrich, Srini Poondru, Andrew Stephens, Tiffany Logan, Karen Hart, Elizabeth Buck, Craig Carden, Colin Lindsay, Stanley Kaye, Edward Kim, Jeff Evans, Igor Puzanov, David Epstein, Mark Miglarese

Mol Cancer Ther (2009) 8 (12_Supplement): A46.

https://doi.org/10.1158/1535-7163.TARG-09-A46

Published: 10 December 2009

View article titled, Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors

Journal Articles

The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells

Sharon Barr, Suzanne Russo, Elizabeth Buck, Stuart Thomson, John Haley, Qun-Sheng Ji, Mark Miglarese, Kenneth Iwata

Mol Cancer Ther (2007) 6 (11_Supplement): A130.

Published: 01 November 2007

View article titled, The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells

Journal Articles

Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade

Elizabeth Buck, Alexandra Eyzaguirre, Stuart Thomson, Sharon Barr, Mark Miglarese, John Haley, Kenneth Iwata

Mol Cancer Ther (2007) 6 (11_Supplement): A128.

Published: 01 November 2007

View article titled, Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade

Journal Articles

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Stuart Thomson, Fillippo Petti, Izabela Sujka-Kwok, Elizabeth Buck, Sharon Barr, Mark Miglarese, John Haley

Mol Cancer Ther (2007) 6 (11_Supplement): A200.

Published: 01 November 2007

View article titled, Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

NARROW

Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines

Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors

The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells

Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Email alerts

AACR Journals

Epithelial–Mesenchymal Transition Predicts Sensitivity to the Dual IGF-1R/IR Inhibitor OSI-906 in Hepatocellular Carcinoma Cell Lines

Abstract A46: Pharmacodynamic biomarkers for OSI‐906, an insulin‐like growth factor‐1 receptor (IGF‐1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors

The EGFR antagonist, erlotinib, combined with a small molecule inhibitor of IGF-1R acts synergistically to inhibit proliferation and induce apoptosis in ovarian and HNSCC cells

Differential effects for small molecule versus antibody inhibitors of EGFR: Erlotinib, but not the neutralizing antibody C225, achieves inhibition of the EGFR-HER3-Akt signaling cascade

Erlotinib sensitivity in NSCLC cell lines correlates with an epithelial to mesenchymal transition which induces a switch in receptor tyrosine kinase signaling.

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only